Patient Characteristics at Baseline: TACE Group Versus TAE Group
| Characteristic | TACE group | TAE group | Statistics |
|---|---|---|---|
| Patients (n) | 31 | 43 | |
| Sex (M/F) (n) | 25/6 | 38/5 | NS |
| Mean age ± SD (y) | 60 ± 9 | 61 ± 11 | NS |
| Etiology of cirrhosis (n) | NS | ||
| Hepatitis B virus | 7 (22%) | 8 (18%) | |
| Hepatitis C virus | 11 (36%) | 11 (26%) | |
| Alcoholic liver disease | 3 (10%) | 6 (14%) | |
| Mixed (virus + alcohol) | 3 (10%) | 3 (7%) | |
| Others | 7 (22%) | 15 (35%) | |
| Child–Pugh grade: A/B/C (n) | 19/10/2 | 24/18/1 | NS |
| Mean MELD score ± SD | 12 ± 3 | 12 ± 4 | NS |
| Number nodules: 1/2/3/≥4 | 17/7/4/3 | 20/11/1/11 | NS |
| Mean largest diameter ± SD (mm) | 47 ± 29 | 54 ± 37 | NS |
| Patent PV/PVT (n) | 29/2 | 39/4 | NS |
| Okuda stage (I/II/III) (n) | 11/17/3 | 15/25/3 | NS |
| CLIP score: 0/1/2/3/4–6 (n) | 7/10/10/1/3 | 7/16/14/4/2 | NS |
| BCLC score: A/B/C/D (n) | 14/15/0/2 | 15/27/0/1 | NS |
NS = not significant; portal vein.